The University of Arizona

Emergency Use

Hotline Graphic

HSPP Contacts

Department email:

*Subscribe to the HSPP listserv

Christine Melton-Lopez, Director 
(520) 626-8630

Courtney Olson, Manager, Process Improvement and Education 
(520) 626-9034

Gina Fimbres-Leon Guerrero, IRB Coordinator
(520) 626-0026

Jessica Winters, IRB Coordinator
(520) 626-0256

Jared Gonzales-Pryor, IRB Coordinator
(520) 626-1744

Alyssa Little, IRB Associate
(520) 626-5859

Jeff Homes, IRB Associate
(520) 626-7889

Joanna Schrader, IRB Associate 
(520) 626-6282

Street Address
1618 E. Helen Street
Tucson, AZ 85721

Mailing Address
POB 210409
Tucson, AZ 85721


Customer Service Survey



The Food and Drug Administration (FDA) defines "emergency use" as the use of a test article (drug, device, or biological product) on a human subject in a life-threatening situation in which no standard acceptable treatment is available, and in which there is not sufficient time to obtain IRB approval [21CFR 56.102 (d)]. The FDA regulates use of all investigational drugs and devices, including emergency use. The IRB must be notified of all emergency use, even though it is not considered research.

Only one emergency use of the test article is permitted at a given institution and any subsequent use must have an IRB approved protocol in place for the use. However, the FDA acknowledges that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue.

Submission Requirements

Effective July 2016, any request for use of an unapproved test article for the treatment and care of a patient in a life-threatening situation at Banner-University Medicine requires IRB oversight from Banner Health IRB.

Robert Flynn - or 480-412-6859 (for questions about operational considerations)

Jenny Maxon - or 602-839-5777 (for questions about IRB submission)

Please see Banner Health’s policy regarding use of Emergency Use here.

For GENERAL instruction on FDA requirements for emergency use of a test article in a life-threatening situation see guidance here.  NOTE: This guidance is not intended for Exception from Informed Consent (EFIC) research, which is a separate category in the FDA rules for research with test articles.